Vaxart, Inc.
VXRT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29 | $7 | $0 | $1 |
| % Growth | 288.9% | 6,796.3% | -88% | – |
| Cost of Goods Sold | $0 | $5 | $0 | $49 |
| Gross Profit | $29 | $3 | $0 | -$48 |
| % Margin | 100% | 39% | 100% | -5,365.1% |
| R&D Expenses | $74 | $68 | $81 | $49 |
| G&A Expenses | $21 | $23 | $29 | $22 |
| SG&A Expenses | $21 | $23 | $29 | $22 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$5 | $4 | -$46 |
| Operating Expenses | $95 | $86 | $115 | $25 |
| Operating Income | -$66 | -$83 | -$115 | -$73 |
| % Margin | -231% | -1,129.5% | -107,090.7% | -8,156.1% |
| Other Income/Exp. Net | -$0 | $1 | $7 | $2 |
| Pre-Tax Income | -$67 | -$82 | -$108 | -$70 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$67 | -$82 | -$108 | -$70 |
| % Margin | -233.3% | -1,117.6% | -100,708.4% | -7,900.2% |
| EPS | -0.14 | -0.17 | -0.22 | -0.14 |
| % Growth | 17.6% | 22.7% | -57.1% | – |
| EPS Diluted | -0.14 | -0.17 | -0.22 | -0.14 |
| Weighted Avg Shares Out | 487 | 487 | 487 | 487 |
| Weighted Avg Shares Out Dil | 487 | 487 | 487 | 487 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $1 | $0 |
| Interest Expense | $3 | $1 | $1 | $1 |
| Depreciation & Amortization | $9 | $9 | $6 | $2 |
| EBITDA | -$55 | -$72 | -$101 | -$66 |
| % Margin | -191.2% | -977.5% | -94,000.9% | -7,449.7% |